Cargando…

Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation

Among the several next-generation tyrosine kinase inhibitors (TKIs) tested against uncommon EFGR alterations, poziotinib has been demonstrated to be a powerful agent for metastatic non-small-cell lung cancer (mNSCLC) with aberrations in HER2 exon 20, and FDA approval is being sought in the previousl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prelaj, Arsela, Bottiglieri, Achille, Bhat, Gajanan, Washington, Rocky, Calareso, Giuseppina, Greco, Gabriella Francesca, Ferrara, Roberto, Brambilla, Marta, De Toma, Alessandro, Occhipinti, Mario, Manglaviti, Sara, Soro, Alberto, Ganzinelli, Monica, Lo Russo, Giuseppe, Proto, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215205/ https://www.ncbi.nlm.nih.gov/pubmed/35756673 http://dx.doi.org/10.3389/fonc.2022.902967

Ejemplares similares

Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy
por: Prelaj, Arsela, et al.
Publicado: (2022)

Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors
por: Occhipinti, Mario, et al.
Publicado: (2021)

Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
por: Le, Xiuning, et al.
Publicado: (2022)

Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations
por: Ferrara, Roberto, et al.
Publicado: (2021)

Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
por: Signorelli, Diego, et al.
Publicado: (2022)

PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
por: Lo Russo, G., et al.
Publicado: (2022)

Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients
por: Prelaj, Arsela, et al.
Publicado: (2023)

Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro
por: Ji, Weiping, et al.
Publicado: (2021)

Diffuse scaly erythematous plaques in patient taking poziotinib
por: Oldenburg, Reid, et al.
Publicado: (2021)

Is hyperprogressive disease a specific phenomenom of immunotherapy?
por: Brambilla, Marta, et al.
Publicado: (2020)

Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials
por: Wang, Bi-Cheng, et al.
Publicado: (2022)

SMO mutations confer poor prognosis in malignant pleural mesothelioma
por: Signorelli, Diego, et al.
Publicado: (2020)

EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort
por: Prelaj, Arsela, et al.
Publicado: (2019)

Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system
por: Prelaj, Arsela, et al.
Publicado: (2020)

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
por: Lo Russo, Giuseppe, et al.
Publicado: (2023)

Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer
por: McCorkle, J. Robert, et al.
Publicado: (2021)

Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS/MS
por: Wang, Shuanghu, et al.
Publicado: (2023)

Combined Poziotinib with Manidipine Treatment Suppresses Ovarian Cancer Stem-Cell Proliferation and Stemness
por: Lee, Heejin, et al.
Publicado: (2020)

Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
por: Kalra, Rashi, et al.
Publicado: (2022)

Assessments of CYP‑inhibition‑based drug–drug interaction between vonoprazan and poziotinib in vitro and in vivo
por: Zhou, Shan, et al.
Publicado: (2023)

Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression
por: Prelaj, Arsela, et al.
Publicado: (2021)

Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method
por: Wang, Jinhui, et al.
Publicado: (2021)

A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
por: Lee, Ji Hyun, et al.
Publicado: (2021)

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
por: Nichetti, Federico, et al.
Publicado: (2019)

Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature
por: Prelaj, Arsela, et al.
Publicado: (2019)

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
por: Kim, Tae Min, et al.
Publicado: (2018)

Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib
por: Tchekmedyian, Nishan, et al.
Publicado: (2020)

Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry
por: Mountzios, Giannis, et al.
Publicado: (2022)

Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
por: Prelaj, Arsela, et al.
Publicado: (2019)

Multimodal treatment for local recurrent malignant gliomas: Resurgery and/or reirradiation followed by chemotherapy
por: Prelaj, Arsela, et al.
Publicado: (2019)

BPS black holes, supersymmetry and orbits of exceptional groups
por: Ferrara, S.
Publicado: (1998)

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib
por: Longo, Vito, et al.
Publicado: (2021)

Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
por: Zhang, Yongchao, et al.
Publicado: (2020)

Exceptional ultraviolet finite Yang-Mills theories
por: Derendinger, Jean-Pierre, et al.
Publicado: (1984)

In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker Genes
por: Alamery, Salman, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy in Neuroendocrine Bladder Cancer: A Case Report
por: Prelaj, Arsela, et al.
Publicado: (2016)

Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC
por: Prelaj, Arsela, et al.
Publicado: (2017)

Orbits of Exceptional Groups, Duality and BPS States in String Theory
por: Ferrara, Sergio, et al.
Publicado: (1997)

An exceptional vaccination policy in exceptional circumstances
por: The Lancet Infectious Diseases
Publicado: (2021)

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
por: Han, Ji-Youn, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hudo27u0v8pehigcob514lpfba